Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome

Suman Rao, Deepak Gurbani, Guangyan Du, Robert A. Everley, Christopher M. Browne, Apirat Chaikuad, Li Tan, Martin Schröder, Sudershan Gondi, Scott B. Ficarro, Taebo Sim, Nam Doo Kim, Matthew J. Berberich, Stefan Knapp, Jarrod A. Marto, Kenneth D Westover, Peter K. Sorger, Nathanael S. Gray

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Covalent kinase inhibitors, which typically target cysteine residues, represent an important class of clinically relevant compounds. Approximately 215 kinases are known to have potentially targetable cysteines distributed across 18 spatially distinct locations proximal to the ATP-binding pocket. However, only 40 kinases have been covalently targeted, with certain cysteine sites being the primary focus. To address this disparity, we have developed a strategy that combines the use of a multi-targeted acrylamide-modified inhibitor, SM1-71, with a suite of complementary chemoproteomic and cellular approaches to identify additional targetable cysteines. Using this single multi-targeted compound, we successfully identified 23 kinases that are amenable to covalent inhibition including MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1, and RSK2. The identification of nine of these kinases previously not targeted by a covalent inhibitor increases the number of targetable kinases and highlights opportunities for covalent kinase inhibitor development. The current work by Rao et al. describes using a promiscuous ligand as a tool to identify new targets for drug discovery. The findings from this study highlight previously unknown targets against which irreversible inhibitors can be developed. These targets are typically deregulated in diseases including cancer.

Original languageEnglish (US)
Pages (from-to)818-829.e9
JournalCell Chemical Biology
Volume26
Issue number6
DOIs
StatePublished - Jun 20 2019

Fingerprint

Cysteine
Phosphotransferases
Acrylamide
Drug Discovery
Adenosine Triphosphate
Ligands
Neoplasms

Keywords

  • chemical probe
  • chemoproteomics
  • covalent inhibitors
  • crystal structure
  • cysteines
  • drug discovery
  • kinase inhibitors
  • kinobeads
  • multi-targeted compounds
  • target engagement

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmacology
  • Drug Discovery
  • Clinical Biochemistry

Cite this

Rao, S., Gurbani, D., Du, G., Everley, R. A., Browne, C. M., Chaikuad, A., ... Gray, N. S. (2019). Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. Cell Chemical Biology, 26(6), 818-829.e9. https://doi.org/10.1016/j.chembiol.2019.02.021

Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. / Rao, Suman; Gurbani, Deepak; Du, Guangyan; Everley, Robert A.; Browne, Christopher M.; Chaikuad, Apirat; Tan, Li; Schröder, Martin; Gondi, Sudershan; Ficarro, Scott B.; Sim, Taebo; Kim, Nam Doo; Berberich, Matthew J.; Knapp, Stefan; Marto, Jarrod A.; Westover, Kenneth D; Sorger, Peter K.; Gray, Nathanael S.

In: Cell Chemical Biology, Vol. 26, No. 6, 20.06.2019, p. 818-829.e9.

Research output: Contribution to journalArticle

Rao, S, Gurbani, D, Du, G, Everley, RA, Browne, CM, Chaikuad, A, Tan, L, Schröder, M, Gondi, S, Ficarro, SB, Sim, T, Kim, ND, Berberich, MJ, Knapp, S, Marto, JA, Westover, KD, Sorger, PK & Gray, NS 2019, 'Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome', Cell Chemical Biology, vol. 26, no. 6, pp. 818-829.e9. https://doi.org/10.1016/j.chembiol.2019.02.021
Rao, Suman ; Gurbani, Deepak ; Du, Guangyan ; Everley, Robert A. ; Browne, Christopher M. ; Chaikuad, Apirat ; Tan, Li ; Schröder, Martin ; Gondi, Sudershan ; Ficarro, Scott B. ; Sim, Taebo ; Kim, Nam Doo ; Berberich, Matthew J. ; Knapp, Stefan ; Marto, Jarrod A. ; Westover, Kenneth D ; Sorger, Peter K. ; Gray, Nathanael S. / Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. In: Cell Chemical Biology. 2019 ; Vol. 26, No. 6. pp. 818-829.e9.
@article{e966332e26b8481a8e6f98e68c295bd7,
title = "Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome",
abstract = "Covalent kinase inhibitors, which typically target cysteine residues, represent an important class of clinically relevant compounds. Approximately 215 kinases are known to have potentially targetable cysteines distributed across 18 spatially distinct locations proximal to the ATP-binding pocket. However, only 40 kinases have been covalently targeted, with certain cysteine sites being the primary focus. To address this disparity, we have developed a strategy that combines the use of a multi-targeted acrylamide-modified inhibitor, SM1-71, with a suite of complementary chemoproteomic and cellular approaches to identify additional targetable cysteines. Using this single multi-targeted compound, we successfully identified 23 kinases that are amenable to covalent inhibition including MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1, and RSK2. The identification of nine of these kinases previously not targeted by a covalent inhibitor increases the number of targetable kinases and highlights opportunities for covalent kinase inhibitor development. The current work by Rao et al. describes using a promiscuous ligand as a tool to identify new targets for drug discovery. The findings from this study highlight previously unknown targets against which irreversible inhibitors can be developed. These targets are typically deregulated in diseases including cancer.",
keywords = "chemical probe, chemoproteomics, covalent inhibitors, crystal structure, cysteines, drug discovery, kinase inhibitors, kinobeads, multi-targeted compounds, target engagement",
author = "Suman Rao and Deepak Gurbani and Guangyan Du and Everley, {Robert A.} and Browne, {Christopher M.} and Apirat Chaikuad and Li Tan and Martin Schr{\"o}der and Sudershan Gondi and Ficarro, {Scott B.} and Taebo Sim and Kim, {Nam Doo} and Berberich, {Matthew J.} and Stefan Knapp and Marto, {Jarrod A.} and Westover, {Kenneth D} and Sorger, {Peter K.} and Gray, {Nathanael S.}",
year = "2019",
month = "6",
day = "20",
doi = "10.1016/j.chembiol.2019.02.021",
language = "English (US)",
volume = "26",
pages = "818--829.e9",
journal = "Cell Chemical Biology",
issn = "2451-9448",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome

AU - Rao, Suman

AU - Gurbani, Deepak

AU - Du, Guangyan

AU - Everley, Robert A.

AU - Browne, Christopher M.

AU - Chaikuad, Apirat

AU - Tan, Li

AU - Schröder, Martin

AU - Gondi, Sudershan

AU - Ficarro, Scott B.

AU - Sim, Taebo

AU - Kim, Nam Doo

AU - Berberich, Matthew J.

AU - Knapp, Stefan

AU - Marto, Jarrod A.

AU - Westover, Kenneth D

AU - Sorger, Peter K.

AU - Gray, Nathanael S.

PY - 2019/6/20

Y1 - 2019/6/20

N2 - Covalent kinase inhibitors, which typically target cysteine residues, represent an important class of clinically relevant compounds. Approximately 215 kinases are known to have potentially targetable cysteines distributed across 18 spatially distinct locations proximal to the ATP-binding pocket. However, only 40 kinases have been covalently targeted, with certain cysteine sites being the primary focus. To address this disparity, we have developed a strategy that combines the use of a multi-targeted acrylamide-modified inhibitor, SM1-71, with a suite of complementary chemoproteomic and cellular approaches to identify additional targetable cysteines. Using this single multi-targeted compound, we successfully identified 23 kinases that are amenable to covalent inhibition including MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1, and RSK2. The identification of nine of these kinases previously not targeted by a covalent inhibitor increases the number of targetable kinases and highlights opportunities for covalent kinase inhibitor development. The current work by Rao et al. describes using a promiscuous ligand as a tool to identify new targets for drug discovery. The findings from this study highlight previously unknown targets against which irreversible inhibitors can be developed. These targets are typically deregulated in diseases including cancer.

AB - Covalent kinase inhibitors, which typically target cysteine residues, represent an important class of clinically relevant compounds. Approximately 215 kinases are known to have potentially targetable cysteines distributed across 18 spatially distinct locations proximal to the ATP-binding pocket. However, only 40 kinases have been covalently targeted, with certain cysteine sites being the primary focus. To address this disparity, we have developed a strategy that combines the use of a multi-targeted acrylamide-modified inhibitor, SM1-71, with a suite of complementary chemoproteomic and cellular approaches to identify additional targetable cysteines. Using this single multi-targeted compound, we successfully identified 23 kinases that are amenable to covalent inhibition including MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1, and RSK2. The identification of nine of these kinases previously not targeted by a covalent inhibitor increases the number of targetable kinases and highlights opportunities for covalent kinase inhibitor development. The current work by Rao et al. describes using a promiscuous ligand as a tool to identify new targets for drug discovery. The findings from this study highlight previously unknown targets against which irreversible inhibitors can be developed. These targets are typically deregulated in diseases including cancer.

KW - chemical probe

KW - chemoproteomics

KW - covalent inhibitors

KW - crystal structure

KW - cysteines

KW - drug discovery

KW - kinase inhibitors

KW - kinobeads

KW - multi-targeted compounds

KW - target engagement

UR - http://www.scopus.com/inward/record.url?scp=85067237871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067237871&partnerID=8YFLogxK

U2 - 10.1016/j.chembiol.2019.02.021

DO - 10.1016/j.chembiol.2019.02.021

M3 - Article

VL - 26

SP - 818-829.e9

JO - Cell Chemical Biology

JF - Cell Chemical Biology

SN - 2451-9448

IS - 6

ER -